{"text_format":"3","workbook":"xlsx","n_sheets":1,"sheets":["Table 2"],"read":"whole","date_system":"1900"}

{"sheet":"Table 2","index":0,"n_rows":41,"n_cols":17,"rows_kept":41,"merged":[[2,2,2,7],[2,9,2,14],[2,16,4,16],[6,2,6,7],[6,9,6,14],[7,2,7,7],[7,9,7,14],[27,2,27,7],[27,9,27,14]]}
["Table 2. Association between plasma concentration of angiopoietin-1, -2 and kenvatinib and presence of continuation of lenvatinib therapy during 1 year"]
[]
["Lenvatinib therapy",null,"Continuous therapy for 1 year",{"$nulls":6},"Withdrawal at less than 1 year",{"$nulls":6},"P-values"]
["Number",{"$nulls":3},18,{"$nulls":6},18]
[null,null,"Median","(","Q1","-","Q3",")",null,"Median","(","Q1","-","Q3",")"]
["Age",null,{"v":67,"d":"67.0"},"(",57.8,"-",{"v":72,"d":"72.0"},")",null,{"v":68,"d":"68.0"},"(",{"v":59,"d":"59.0"},"-",{"v":74,"d":"74.0"},")",null,0.584]
["Female : Male",null,"10 : 8",{"$nulls":6},"13 : 5",{"$nulls":6},0.489]
["PTC/FTC/MTC/PDTC/ATC",null,"9/5/0/4/0",{"$nulls":6},"4/3/1/0/10",{"$nulls":6},2E-3]
["Angiopoietin-1"]
[" Before lenvatinib therapy (baseline) (pg/mL)",null,6459,"(",4311,"-",7209,")",null,6833,"(",5250,"-",8750,")",null,0.118]
[" 1 month after lenvatinib treatment (pg/mL)",null,5750,"(",4146,"-",7250,")",null,5417,"(",4667,"-",6083,")","**",0.406]
[" 1 year after lenvatinib treatment (pg/mL)",null,5625,"(",4490,"-",7458,")"]
[" Change on 1 month from baseline (%)",null,"-9.2","(","-19.8","-",10.1,")",null,"-25.1","(","-34.0","-",1.6,")",null,0.068]
[" Change on 1 year from baseline (%)",null,3.3,"(","-18.0","-",20.4,")"]
["Angiopoietin-2"]
[" Before lenvatinib therapy (baseline) (pg/mL)",null,1590,"(",1375,"-",2237,")",null,1773,"(",1205,"-",2986,")",null,{"v":1,"d":"1.000"}]
[" 1 month after lenvatinib treatment (pg/mL)",null,968,"(",687,"-",1245,")","***",936,"(",830,"-",1649,")","*",0.673]
[" 1 year after lenvatinib treatment (pg/mL)",null,1015,"(",887,"-",1394,")","***"]
[" Change on 1 month from baseline (%)",null,"-51.0","(","-60.0","-","-35.2",")",null,"-46.1","(","-58.2","-","-16.1",")",null,0.501]
[" Change on 1 year from baseline (%)",null,"-40.2","(","-53.8","-","-29.1",")"]
["Angiopoietin-2/angiopoietin-1 ratio"]
[" Before lenvatinib therapy (baseline)",null,{"v":0.3,"d":"0.30"},"(",0.19,"-",0.52,")",null,0.28,"(",{"v":0.2,"d":"0.20"},"-",0.42,")",null,0.584]
[" 1 month after lenvatinib treatment",null,0.13,"(",0.12,"-",0.35,")","***",0.22,"(",0.13,"-",0.33,")",null,0.443]
[" 1 year after lenvatinib treatment",null,0.19,"(",0.14,"-",0.25,")","***"]
["Lenvatinib"]
[" C0 on 1 month after lenvatinib treatment (ng/mL)",null,{"v":82,"d":"82.0"},"(",64.7,"-",181,")",null,108,"(",58.3,"-",152,")",null,0.606]
[" C0 on 1 year after lenvatinib treatment (ng/mL)",null,59.7,"(",{"v":37,"d":"37.0"},"-",113,")","##"]
["PTC/FTC",null,"9/5",{"$nulls":6},"4/3",{"$nulls":6},{"v":1,"d":"1.000"}]
["Angiopoietin 1"]
[" Before lenvatinib therapy (baseline) (pg/mL)",null,6459,"(",4224,"-",8083,")",null,6833,"(",5250,"-",8750,")",null,0.322]
[" 1 month after lenvatinib treatment (pg/mL)",null,6084,"(",3771,"-",7250,")",null,5326,"(",4917,"-",6648,")",null,0.743]
[" Change on 1 month from baseline (%)",null,"-10.8","(","-19.8","-",4.9,")",null,"-28.0","(","-42.9","-",4.4,")",null,0.172]
["Angiopoietin 2"]
[" Before lenvatinib therapy (baseline) (pg/mL)",null,1790,"(",1448,"-",2237,")",null,1752,"(",1399,"-",3493,")",null,0.799]
[" 1 month after lenvatinib treatment (pg/mL)",null,999,"(",754,"-",1387,")","***",1212,"(",886,"-",11305,")",null,0.197]
[" Change on 1 month from baseline (%)",null,"-45.9","(","-54.4","-","-27.5",")",null,"-30.0","(","-49.4","-","230",")",null,0.197]
[]
["Q: quartile"]
["PTC: papillary thyroid cancer, FTC: follicular thyroid cancer, MTC: medullary thyroid cancer, PDTC: poorly differentiated thyroid cancer, ATC: anaplastic thyroid cancer "]
["* P< 0.05, ** P<0.01, *** P<0.001 vs baseline"]
["## P<0.01 vs 1 month after lenvatinib therapy"]